| Name | Title | Contact Details |
|---|
Avaxia is a leader in the growing field of gut-targeted therapeutics — orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal tract. Avaxia’s lead clinical candidate, AVX-470, is an oral anti-TNF antibody for inflammatory bowel disease. This transformative product offers potentially improved safety and efficacy over existing anti-TNF therapies by focusing immune suppression only where needed in the diseased gut. Avaxia plans to use its gut-targeted antibody platform to develop therapeutics to address many other serious diseases such as type 2 diabetes, celiac disease, GI acute radiation syndrome and oral mucositis.
AFYA Inc is a Laurel, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Inflo Health is a company that helps imaging centers and hospitals realize more revenue and provide the best patient outcomes.
Washington and West is a Towson, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Blue Ridge Medical Imaging is a Salem, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.